of cerebral oedema and inflammatory cytokines and, more recently, ideas on interorgan ammonia trafficking often had their first airing at these gatherings.
Some clues for a progress in the understanding of this syndrome regard the changes occurring into the brain due to ammonia (Butterworth 2003; Haussinger 2006; Norenberg et al. 2007 ) and body ammonia trafficking (Olde Damink et al. 2002a, b; Romero-Gomez et al. 2006 ). In addition, new features of brain-liver interaction are appearing on the horizon and are worthy of consideration: a detrimental influence of HCV virus on cognitive function and wellbeing (Forton et al. 2001) , either related to the virus per se or to systemic or brain inflammatory response; the influence of liver transplantation and immunosuppressive agents on the brain (Amodio et al. 2007) ; the renewed interest for nutrition, microelements deficiency, notably-but not only-thiamine; and the consequences of alcohol misuse (Butterworth 1995; Kalaitzakis et al. 2007) .
Treatment for hepatic encephalopathy is still based, somewhat empirically, on our concepts of the pathogenesis of the syndrome and so primarily on methods to prevent the production, absorption and elimination of ammonia. Newer treatment approaches are mooted, but progress often frustrating slow, despite the fact that hepatic encephalopathy is one of the most serious consequences of severe liver disease. In fact, i) HE is the hallmark of acute liver failure (O'Grady et al. 1993) ; ii) episodes of HE concern about 10% of patients with compensated cirrhosis and about 40% of patients with decompensated cirrhosis in a 5 year follow up (D'Amico et al. 1986; Ginés et al. 1987) , iii) HE complicates about 20% of TIPPS procedure greatly reducing the quality of life iv) HE, even in its minimal expression, is a marker of low survival expectancy (Merkel et al. 1989; Bustamante et al. 1999; Romero-Gomez et al. 2001; Amodio et al. 2001; Stewart et al. 2007) .
Progress in determining a 'gold standard' for the diagnosis of this condition represents an extraordinary challenge for instrumental techniques: structural and functional brain imaging, neurophysiology, neuropsychology and psychophysiology. Even basic clinical classification of behavior and motor alterations need to be further focused to detect and properly represent HE.
All these areas have been delineated and debated and have been added to the 'standing agenda' for the meetings.
The long-standing informal relationship between neuroscientists and hepatologists involved in this field was recently formalized by the creation of the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN). The first formal meeting of this society, the thirteenth meeting since 1972, was held in Padua, Italy in May 2008 (A. a 2008 . This issue of Metabolic Brain Diseases contains some of the invited lectures designed to clarify some of the more important issues in this field.
